-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy for Hematological Malignancy and Solid Tumor in Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy for Hematological Malignancy and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UBX-1325 in Choroidal Neovascularization
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.UBX-1325 in Choroidal Neovascularization Drug Details:UBX-1325 is under development for the treatment of ophthalmological diseases such...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gemogenovatucel-T in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gemogenovatucel-T in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gemogenovatucel-T in Cervical Cancer Drug Details: Gemogenovatucel-T (Vigil) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Budigalimab in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Budigalimab in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Budigalimab in Laryngeal CancerDrug Details:Budigalimab (ABBV-181) is under development for the treatment of...
-
Product Insights
Net Present Value Model: UBX-1325
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model UBX-1325 Drug Details UBX-1325 is under...
-
Product Insights
Net Present Value Model: UBX-1967
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model UBX-1967 Drug Details UBX-1967 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – UBX-1325
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry UBX-1325 Drug Details UBX-1325 is under development for the treatment of ophthalmological diseases such...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – UBX-1967
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry UBX-1967 Drug Details UBX-1967 is under development for the treatment of diabetic macular edema,  diabetic...
-
Company Insights
UnionBank of the Philippines – Enterprise Tech Ecosystem Series
UnionBank of the Philippines (UnionBank) offers personal banking, investment and trust business banking, and other related financial solutions and services. Its portfolio of offerings comprises a range of accounts and deposit services, which includes savings, checking, and time deposits; card products such as debit, credit, and prepaid cards; and lending solutions for home, motor, personal requirements, businesses, mortgages, and corporates. UnionBank has embraced digital technologies like mobile, conversational platforms, blockchain, and data analytics as well as digital engagement channels to...